CIK 0001609809
- Non-accelerated filer
- Smaller reporting company
Seres Therapeutics, Inc.
Sign in to watch- Ticker
- MCRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 274326290
- Phone
- +1 617-945-9626
- Business address
- 200 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- Seres Therapeutics, Inc., Seres Health, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $795
- in 4 filings, $795 under 10b5-1 plans
Net −$795. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-22 | Behar Gregory Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2022-06-22 | Ausiello Dennis A Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2022-06-22 | Berenson Stephen Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2022-06-22 | Dere Willard H Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2022-06-15 | Arkowitz David Chief Financial Officer | Exercise or conversion | +5,000 | 70,492 | ||
| 2022-06-15 | Arkowitz David Chief Financial Officer | Exercise or conversion · Restricted Stock Units | −5,000 | 0 | ||
| 2022-02-07 | Cloghessy Paula | Grant or award · Stock Options (right to buy) | +190,000 | 190,000 | ||
| 2022-02-04 | Ege David S. | Grant or award · Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2022-02-04 | Young Teresa L. | Grant or award · Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2022-02-04 | von Moltke Lisa | Grant or award · Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2022-02-04 | Arkowitz David | Grant or award · Stock Option (Right to Buy) | +190,000 | 190,000 | ||
| 2022-02-04 | Shaff Eric D. President, CEO | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2022-02-04 | DesRosier Thomas Chief Legal Officer and EVP | Grant or award · Stock Option (Right to Buy) | +130,000 | 130,000 | ||
| 2022-02-04 | Henn Matthew R. | Grant or award · Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2021-06-16 | Biondi Paul Director | Grant or award · Stock Option (right to buy) | +23,000 | 23,000 | ||
| 2021-06-16 | Berenson Stephen Director | Grant or award · Stock Option (right to buy) | +23,000 | 23,000 | ||
| 2021-06-16 | Ausiello Dennis A Director | Grant or award · Stock Option (right to buy) | +23,000 | 23,000 | ||
| 2021-06-16 | Graves Kurt Director | Grant or award · Stock Option (right to buy) | +23,000 | 23,000 | ||
| 2021-06-16 | Behar Gregory Director | Grant or award · Stock Option (right to buy) | +23,000 | 23,000 | ||
| 2021-06-16 | Dere Willard H Director | Grant or award · Stock Option (right to buy) | +23,000 | 23,000 |
Page 21 of 23 · 458 trades